Open Lecture Series on Next Frontiers in IPEDs Research

Organized by the Mindful Muscles Early Career Researchers’ Community of Practice.

Do you want to know more about the latest evidence on the effects of Anabolic Androgenic Steroid (AAS) use on health? Then join us online on Thursday, March 3rd, 14.00 – 15.30 (GMT) to attend the first lecture of the 2022 Open Lecture Series on Next Frontiers in IPEDs Research organized by the Mindful Muscles Early Career Researchers’ Community of Practice. 

Dr Diederik Smit from the Department of Internal Medicine, Spaarne Gasthuis (Haarlem) and ETZ Hospital (Tilburg), the Netherlands, will present the topic:

Health effects of androgen abuse. Experiences from the outpatient AAS clinic and results from the HAARLEM study.

The presentation can be joined by using the following link on March 3rd, 14:00 – 15:30 (GMT):

Some information about Diederik Smit’s work:

The ‘Anabolenpoli’ or AAS clinic, an outpatient clinic for past and current users of AAS, was established more than a decade ago. It was the only clinic worldwide that focuses primarily on helping patients with health problems related to AAS use. Recently, a second clinic opened in the Netherlands. A physician specialized in health effects from AAS use can therefore be reached readily by patients throughout the country.

From 2015 – 2018 the specialists behind the AAS clinic, Dr Diederik Smit and Dr Pim de Ronde, conducted a prospective observational study with a systematic approach, the HAARLEM study. The goal of the study was to obtain more reliable information about the health effects of AAS use. A cohort of 100 men was assembled, and health analyses and measurements of physiological and mental status were performed during a 1- year follow- up period: before, during, and after a cycle of androgens. This has resulted in a unique series of publications that can be found here.

In his presentation, Dr Diederik Smit will tell about his experiences at the AAS clinic, the results of the HAARLEM study, and about the new prospective cohort study that will start in 2022: the HARNAS-trial.